Global interim Phase 2 data in extensive-stage small cell lung cancer presented at #WCLC25: Investigational approach designed to target PD-L1 and VEGF-A in a single molecule. Full PR: https://t.co/HAf3GEv8v1

Visit us at Booth #106.

Small cell lung cancer is a key focus at #BioNTech with multiple trials across disease stages. At #WCLC25, we share global interim Phase 2 data on our PD-L1xVEGF-A bispecific antibody candidate in extensive-stage small cell lung cancer.

We are partnering with @bmsnews to jointly develop and commercialize our PD-L1xVEGF bispecific #antibody candidate BNT327. Combining our expertise, resources, and global reach, we aim to bring novel combination therapies to patients with #cancer. 🚀 https://t.co/bh0xVQCY17

🔗 Highlights of our oncology programs to be presented at ASCO: 

At #BioNTech, we’re looking forward to #ASCO25, presenting oncology pipeline progress: mRNA cancer immunotherapies, ADCs, and next-gen immunomodulators and targeted therapies. 🗓 May 30 – June 3 | Chicago 📍 Booth #35165 #CancerResearch #ImmunoOncology #OncologyInnovation

🔗 Read more about our Q1 updates (including our forward-looking statements):

Today, we shared our Q1 2025 results and updates on our business & pipeline. We also shared the news on a leadership transition: Jens Holstein will retire as planned and hand over the #newCFO role to Ramón Zapata as of July 1. Thank you, Jens! And welcome, Ramón Zapata. #BioNTech

Explore more about the data:

At #AACR25, we will present data from our #mRNA and immuno-oncology priority programs. These data support execution of our combination strategy in oncology, including first data on the novel combination of our PD-L1xVEGF-A antibody candidate in combination with #ADCs.

We aim to tackle one of the most lethal cancers worldwide: #LungCancer. This week, we are joining the global community at the #ELCC25 presenting new data for our PD-L1/VEGF-A bispecific antibody candidate in metastatic #SCLC. 👉Learn more about the data: https://t.co/NSxFAZLtHA

👉Link to PR and forward-looking statements disclaimer:

🚀 Update: We completed the acquisition of Biotheus. This strengthens our capabilities to develop, manufacture and commercialize next-gen bispecific antibodies, including BNT327 (PD-L1xVEGF-A bispecific), and supports the global execution of our oncology strategy.

📊 Interim Ph1b/2 data for anti-PD-L1/VEGF-A bispecific antibody candidate BNT327 show a 73.8% cORR and a manageable safety profile (primary endpoints) with a mature 18-month OS rate of 69.7% (secondary endpoint) in 1L TNBC at #SABCS24. 👉 Find out more:

We are excited to be attending this year’s #SABCS24, with new interim Phase 1b/2 data for our anti-PD-L1/VEGF-A bispecific antibody candidate BNT327/PM8002 in triple-negative #BreastCancer (#TNBC). 📍Visit us at booth # 226 to explore the latest data for this asset.

Advancing our oncology strategy: by strengthening next-gen immuno-modulator capabilities, we’re enhancing one core pillar of our oncology strategy.With investigational assets like BNT327/PM8002,our pipeline aims to build a new backbone in immuno-oncology. https://t.co/gG15J8tGtE

We are excited to present updates for our #oncology pipeline at #ESMO24. Presentations feature candidates across multiple modalities which are important backbones for our combination treatment strategy & may open up new synergistic mechanisms of action.👉 https://t.co/zu4BIXRTdC

We have just announced that our personalized #mRNA candidate BNT111 met its primary endpoint in randomized Ph 2 trial, demonstrating a statistically significant improvement in ORR in patients with anti-PD1 refractory/resistant #melanoma. 👉Read more: https://t.co/z6w8irRUkx

The @US_FDA granted Fast Track designation for our #ADC candidate BNT324/DB-1311 for the treatment of castration-resistant #ProstateCancer. With this, all 3 clinical ADC candidates in our collab with #DualityBio have received Fast Track designation. https://t.co/22Gy2j7hqa

📊 Clinical trial data presentation for programs from our immuno-oncology pipeline & real-world data from 2 observational trials. 👉Explore our updates: